5 February - Novo Nordisk today published the full-year financial report for 2019.
Lars Fruergaard Jørgensen, president and CEO: "We are very satisfied with the financial performance in 2019. The results reflect an accelerated sales growth in International Operations and a strong launch of Ozempic® in particular in North America Operations and Region Europe. The Rybelsus® launch in the USA is off to a good start, and we are pleased with the CV label indication for Ozempic® in the USA and the EU recommendation to approve Rybelsus®, all for the benefit of patients."
31 January - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Rybelsus® (oral semaglutide) for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise
“We are very excited about the positive opinion for Rybelsus®, as it is the first and only GLP-1 in a tablet, and we believe it has the potential to set a new standard for the treatment of type 2 diabetes in the EU,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer. “A high proportion of people with type 2 diabetes does not achieve target blood sugar levels, which underpins the need for new and more efficacious solutions to better manage their disease.”
20 November - Novo Nordisk and UNICEF have announced a new partnership to help prevent childhood overweight and obesity worldwide with an initial focus on interventions in Latin America and the Caribbean.
Under this partnership, the United Nations children’s agency and the global healthcare company will combine efforts to enhance knowledge and awareness on how to prevent overweight and obesity and address their root causes. The partnership will initially cover a period of three years.
“There is no doubt that childhood overweight and obesity is a public health crisis that requires immediate attention. Childhood overweight and obesity is more than an individual choice, this is everybody’s business. Together with UNICEF, we hope to help millions of children lead healthy lives and at the same time ease the burden of obesity to society,” said Novo Nordisk President and CEO Lars Fruergaard Jørgensen.
China is facing a diabetes crisis, with more than one in 10 people living with the condition. The Chinese government, however, is fighting back with ambitious plans to deploy the latest technology to bring the epidemic under control, as Novo Nordisk CEO Lars Fruergaard Jørgensen saw for himself during a recent visit.
What if medicines injected by millions could be delivered in tablets?
After almost 100 years of delivering injectable therapies, Novo
Nordisk’s R&D team is finding answers to this enduring question.
Chief Science Officer Mads Krogsgaard Thomsen is leading the way and
he reflects on the magnitude of the scientific challenge and the
progress made in his laboratories.
Novo Nordisk intends to achieve the target to use only renewable electricity in
its global production facilities by 2020. The announcement on 30
April followed a new investment in a 672-acre solar panel
installation, roughly the size of 500 football fields, in North
Carolina, US, which will provide power to Novo Nordisk’s entire US
operations from early 2020. Novo Nordisk is the first pharmaceutical
to use only renewable electricity
in production. RE100 is a collaborative, global initiative of
businesses committed to using 100% renewable electricity.
Read more about Circular
for Zero and download
the full press release on the environmental ambitions
The International Committee of the Red Cross (ICRC), the Danish Red
Cross (DRC) and Novo Nordisk have partnered to tackle the growing
issue of chronic diseases that affect millions of people living in
humanitarian crises around the world. Focus will be on ensuring
efficient supply of low-cost human insulin in vials to Red Cross
globally; support for ICRC’s and DRC’s health programmes; 2-3 projects
to provide care to people with hypertension and diabetes in
humanitarian crises to be conducted within three years.
6 May - first quarter
6 August - first 6 months
30 October - first 9 months
When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years.